{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:34:36Z","timestamp":1794746076234,"version":"4.9.1"},"reference-count":54,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2025,6,2]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease worldwide. Weight loss, achieved by changes to lifestyle behaviours, is the recommended management approach. However, patients find this challenging. A MASLD-specific digital behavioural intervention (interVention to promote lIfesTyle change in metabolic dysfunction-Associated steatotic LIver diseaSE, VITALISE) to target changes in dietary and physical activity behaviours was developed to support weight loss. This study assessed the feasibility and acceptability of delivering VITALISE in routine secondary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-centre, one-arm feasibility study recruited participants from November 2022 to May 2023. VITALISE included MASLD-specific education, provision of self-regulation tools (ie, goal setting, food monitoring, step tracking, weight monitoring) and monthly health coaching appointments by telephone. Patients had access to VITALISE for 6\u2009months. Primary outcomes were feasibility (recruitment, uptake, engagement, adherence, and follow-up rates) and acceptability (patient views). Secondary outcomes were body weight, liver enzymes, liver stiffness, blood pressure, lipid profile, glycated hemoglobin (HbA1c), physical activity and patient activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>35 patients (mean age 54 years; 69% male) with MASLD were recruited to VITALISE (recruitment rate 59%). Of the 35 enrolled, 83% activated their VITALISE account. Patient interviews supported acceptability. At 6\u2009months, mean weight loss was 4.0\u2009kg (3.5%) and alanine transaminase reduced by 27%. A decrease in daily sedentary time and an increase in light physical activity were observed. Self-reported leisure-time physical activity and patient activation increased from baseline to 6-month follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>VITALISE was feasible and acceptable to deliver in routine secondary care. Weight loss and improvements in lifestyle behaviours and liver enzymes were observed. Findings will inform intervention optimisation and future large-scale evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN12893503\">ISRCTN12893503<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2025-001771","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T14:25:21Z","timestamp":1751293521000},"page":"e001771","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Feasibility of a digital lifestyle intervention (VITALISE) to support weight loss in patients with MASLD in routine secondary care"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"isrctn12893503","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn12893503","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3578-1209","authenticated-orcid":false,"given":"Leah","family":"Avery","sequence":"first","affiliation":[{"name":"Centre for Rehabilitation, School of Health and Life Sciences, Teesside University, Middlesbrough, UK"},{"name":"Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3814-6702","authenticated-orcid":false,"given":"Hollie","family":"Smith","sequence":"additional","affiliation":[{"name":"Centre for Rehabilitation, School of Health and Life Sciences, Teesside University, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Livingston","sequence":"additional","affiliation":[{"name":"School of Social Sciences Humanities and Law, Teesside University, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5638-2453","authenticated-orcid":false,"given":"Stuart","family":"McPherson","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"},{"name":"Liver Unit, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK"},{"name":"NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Innerd","sequence":"additional","affiliation":[{"name":"Centre for Rehabilitation, School of Health and Life Sciences, Teesside University, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Hallsworth","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"},{"name":"Liver Unit, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK"},{"name":"NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"2026010701052856000_12.1.e001771.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101133"},{"key":"2026010701052856000_12.1.e001771.2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25762"},{"key":"2026010701052856000_12.1.e001771.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04724.x"},{"key":"2026010701052856000_12.1.e001771.4","doi-asserted-by":"publisher","DOI":"10.1159\/000336669"},{"key":"2026010701052856000_12.1.e001771.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.171"},{"key":"2026010701052856000_12.1.e001771.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"2026010701052856000_12.1.e001771.7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30154-2"},{"key":"2026010701052856000_12.1.e001771.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100897","article-title":"National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022","volume":"5","author":"Li","year":"2023","journal-title":"JHEP Rep"},{"key":"2026010701052856000_12.1.e001771.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2021.100411","article-title":"Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions","volume":"4","author":"Anstee","year":"2022","journal-title":"JHEP Reports"},{"key":"2026010701052856000_12.1.e001771.10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"2026010701052856000_12.1.e001771.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"2026010701052856000_12.1.e001771.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4428","article-title":"Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance","volume":"354","author":"Glen","year":"2016","journal-title":"BMJ"},{"key":"2026010701052856000_12.1.e001771.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.10.008"},{"key":"2026010701052856000_12.1.e001771.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.016"},{"key":"2026010701052856000_12.1.e001771.15","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.cgh.2017.06.011","article-title":"Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice","volume":"15","author":"Avery","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026010701052856000_12.1.e001771.16","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/tbm\/ibz080","article-title":"Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study","volume":"10","author":"Hallsworth","year":"2020","journal-title":"Transl Behav Med"},{"key":"2026010701052856000_12.1.e001771.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2021-000634","article-title":"Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study","volume":"8","author":"Tincopa","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"key":"2026010701052856000_12.1.e001771.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e2333","article-title":"Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care","volume":"344","author":"Khunti","year":"2012","journal-title":"BMJ"},{"key":"2026010701052856000_12.1.e001771.19","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00509-2020","article-title":"Predictors of pulmonary rehabilitation completion in the UK","volume":"7","author":"Stone","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026010701052856000_12.1.e001771.20","doi-asserted-by":"publisher","DOI":"10.1111\/jhn.12273"},{"key":"2026010701052856000_12.1.e001771.21","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6874-14-59"},{"key":"2026010701052856000_12.1.e001771.22","doi-asserted-by":"publisher","DOI":"10.1186\/s12966-023-01424-2"},{"key":"2026010701052856000_12.1.e001771.23","unstructured":"Eldredge LKB , Markham CM , Ruiter RAC , et al . Planning health promotion programs: an intervention mapping approach. Wiley, 2016."},{"key":"2026010701052856000_12.1.e001771.24","doi-asserted-by":"crossref","DOI":"10.2196\/20491","article-title":"Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping","volume":"23","author":"Hallsworth","year":"2021","journal-title":"J Med Internet Res"},{"key":"2026010701052856000_12.1.e001771.25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150205","article-title":"Defining Feasibility and Pilot Studies in Preparation for Randomised Controlled Trials: Development of a Conceptual Framework","volume":"11","author":"Eldridge","year":"2016","journal-title":"PLoS One"},{"key":"2026010701052856000_12.1.e001771.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i5239","article-title":"CONSORT 2010 statement: extension to randomised pilot and feasibility trials","volume":"355","author":"Eldridge","year":"2016","journal-title":"BMJ"},{"key":"2026010701052856000_12.1.e001771.27","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2020-101480"},{"key":"2026010701052856000_12.1.e001771.28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40814-023-01286-2","article-title":"Feasibility and acceptability of an evidence-informed digital intervention to support self-management in people with non-alcoholic fatty liver disease: protocol for a non-randomised feasibility study (VITALISE)","volume":"9","author":"Avery","year":"2023","journal-title":"Pilot Feasibility Stud"},{"key":"2026010701052856000_12.1.e001771.29","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-15-264","article-title":"Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study","volume":"15","author":"Teare","year":"2014","journal-title":"Trials"},{"key":"2026010701052856000_12.1.e001771.30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.15517\/ap.v30i121.23458","article-title":"Health Action Process Approach (HAPA) as a Theoretical Framework to Understand Behavior Change","volume":"30","author":"Schwarzer","year":"2016","journal-title":"AP"},{"key":"2026010701052856000_12.1.e001771.31","doi-asserted-by":"publisher","DOI":"10.1007\/s12160-013-9486-6"},{"key":"2026010701052856000_12.1.e001771.32","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13071236","article-title":"Liver Ultrasound Elastography in Non-Alcoholic Fatty Liver Disease: A State-of-the-Art Summary","volume":"13","author":"Villani","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"2026010701052856000_12.1.e001771.33","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21496"},{"key":"2026010701052856000_12.1.e001771.34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178"},{"key":"2026010701052856000_12.1.e001771.35","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"key":"2026010701052856000_12.1.e001771.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2005.00438.x"},{"key":"2026010701052856000_12.1.e001771.37","doi-asserted-by":"publisher","DOI":"10.1249\/01.mss.0000185657.86065.98"},{"key":"2026010701052856000_12.1.e001771.38","article-title":"Measuring Physical Activity in Free-Living Conditions-Comparison of Three Accelerometry-Based Methods","volume":"7","author":"Leinonen","year":"2016","journal-title":"Front Physiol"},{"key":"2026010701052856000_12.1.e001771.39","doi-asserted-by":"publisher","DOI":"10.1097\/00005768-199805000-00021"},{"key":"2026010701052856000_12.1.e001771.40","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00005768-199706001-00009","article-title":"Godin Leisure-Time Exercise Questionnaire","volume":"29","author":"Godin","year":"1997","journal-title":"Med Sci Sports Exerc"},{"key":"2026010701052856000_12.1.e001771.41","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"2026010701052856000_12.1.e001771.42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11892-017-0948-2","article-title":"A Review of Technology-Assisted Interventions for Diabetes Prevention","volume":"17","author":"Grock","year":"2017","journal-title":"Curr Diab Rep"},{"key":"2026010701052856000_12.1.e001771.43","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000859"},{"key":"2026010701052856000_12.1.e001771.44","doi-asserted-by":"crossref","DOI":"10.2196\/11250","article-title":"Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study","volume":"21","author":"Pfirrmann","year":"2019","journal-title":"J Med Internet Res"},{"key":"2026010701052856000_12.1.e001771.45","doi-asserted-by":"crossref","DOI":"10.2196\/14802","article-title":"Lifestyle Intervention Enabled by Mobile Technology on Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial","volume":"8","author":"Lim","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"key":"2026010701052856000_12.1.e001771.46","doi-asserted-by":"crossref","DOI":"10.2196\/52576","article-title":"User Engagement, Acceptability, and Clinical Markers in a Digital Health Program for Nonalcoholic Fatty Liver Disease: Prospective, Single-Arm Feasibility Study","volume":"8","author":"Bj\u00f6rnsdottir","year":"2024","journal-title":"JMIR Cardio"},{"key":"2026010701052856000_12.1.e001771.47","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000499","article-title":"Digital therapeutics lead to clinically significant body weight loss in patients with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis","volume":"8","author":"Albhaisi","year":"2024","journal-title":"Hepatol Commun"},{"key":"2026010701052856000_12.1.e001771.48","unstructured":"Nwokedi V . 7. Digital inclusion and sustainable development goals: the role of the libraries. International Journal of Educational Research and Development; 2020.1\u20136. Available: https:\/\/www.academeresearchjournals.org\/download.php?id=103726212630782556.pdf&type=application\/pdf&op=1=]"},{"key":"2026010701052856000_12.1.e001771.49","doi-asserted-by":"publisher","DOI":"10.1177\/1090198119873915"},{"key":"2026010701052856000_12.1.e001771.50","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s41347-024-00388-9","article-title":"Engagement with Digital Weight Loss Intervention Components and Weight Outcomes","volume":"9","author":"Whiteley","year":"2024","journal-title":"J technol behav sci"},{"key":"2026010701052856000_12.1.e001771.51","doi-asserted-by":"crossref","DOI":"10.2196\/10471","article-title":"The Association Between Engagement and Weight Loss Through Personal Coaching and Cell Phone Interventions in Young Adults: Randomized Controlled Trial","volume":"6","author":"Lin","year":"2018","journal-title":"JMIR Mhealth Uhealth"},{"key":"2026010701052856000_12.1.e001771.52","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12196216","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective","volume":"12","author":"Eskridge","year":"2023","journal-title":"J Clin Med"},{"key":"2026010701052856000_12.1.e001771.53","doi-asserted-by":"crossref","DOI":"10.2196\/35120","article-title":"Challenges in Participant Engagement and Retention Using Mobile Health Apps: Literature Review","volume":"24","author":"Amagai","year":"2022","journal-title":"J Med Internet Res"},{"key":"2026010701052856000_12.1.e001771.54","doi-asserted-by":"crossref","DOI":"10.2196\/12612","article-title":"Assessment of the Efficacy, Safety, and Effectiveness of Weight Control and Obesity Management Mobile Health Interventions: Systematic Review","volume":"7","author":"Puigdomenech Puig","year":"2019","journal-title":"JMIR Mhealth Uhealth"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2025-001771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:05:58Z","timestamp":1767776758000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2025-001771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6,30]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bmjgast-2025-001771"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2025-001771","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}